The i-STAT TBI Plasma test, in conjunction with other clinical information, assists in determining the need for a CT in adults. It measures the levels of 2 complementary, brain-specific biomarkers, glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), in a single, multiplex test. Results are available in approximately 15 minutes after preparing a plasma sample. With a negative predictive value (NPV) of 99.3% and a clinical sensitivity of 95.8%, the i-STAT TBI Plasma Test can decrease unnecessary CT by up to 40%.1,2 The TBI test can provide confidence by aiding decisions for the safe discharge of patients without performing CT. Reducing unnecessary CT may have positive implications for ED workflow, resource utilization, and patient satisfaction.
1. i-STAT TBI Plasma Cartridge. Instructions for use. Abbott Point of Care Inc. Abbott Park, IL; 2021. 2. Data on file. Abbott Point of Care Inc
Abbott Point of Care
For in vitro diagnostic use only. i-STAT and Alinity are trademarks of Abbott. For intended use and complete product information, visit www.pointofcare.abbott.